Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Jul 23, 2014
Sangamo BioSciences Reports Second Quarter 2014 Financial Results

Jul 16, 2014
Sangamo BioSciences Announces Second Quarter 2014 Conference Call And Webcast


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
12.53
Change:
+ 0.10
Day High:
12.92
Day Low:
12.33
Volume:
768,400
4:00 PM ET on Jul 30, 2014

Shareholder Tools